🇺🇸 FDA
Pipeline program

ASTX727, YERVOY 5 mg/ml concentrate for solution for infusion, OPDIVO 10 mg/mL concentrate for solution for infusion.

NIBIT-ML-1

Phase 2 small_molecule active

Quick answer

ASTX727, YERVOY 5 mg/ml concentrate for solution for infusion, OPDIVO 10 mg/mL concentrate for solution for infusion. for MM and NSCLC patients resistant to anti-PD-1/PD-L1 therapy is a Phase 2 program (small_molecule) at Fondazione Telethon ETS with 1 ClinicalTrials.gov record(s).

Program details

Company
Fondazione Telethon ETS
Indication
MM and NSCLC patients resistant to anti-PD-1/PD-L1 therapy
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials